Lejia Sun1, Qing Wang2, Meixi Liu3, Gang Xu1, Huanhuan Yin3, Dongyue Wang3, Feihu Xie1, Bao Jin1, Yukai Jin1, Huayu Yang1, Junying Zhou4, Yilei Mao5. 1. Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, 100730, Beijing, China. 2. Department of Medical Examination Center, Hebei General Hospital, Shijiazhuang, 050051, China. 3. Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, 100730, Beijing, China. 4. Department of Infectious Disease, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, China. doctorzhoujy@163.com. 5. Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, 100730, Beijing, China. pumch-liver@hotmail.com.
Abstract
PURPOSE: Indicators to assess early liver damage and disease progression in nonalcoholic fatty liver disease (NAFLD) remain unsatisfactory. Albumin binding function has been reported to be an early indicator of liver damage in hepatitis and liver cirrhosis. However, its role in NAFLD patients is unknown. METHODS: An age/sex-matched, case-control study was performed. Albumin-binding capacity (ABiC) and albumin metal ion binding ability, assessed by ischemia modified albumin (IMA), were measured. Correlation analysis was performed to assess the association of albumin binding function with liver function enzymes and noninvasive liver fibrosis markers. RESULTS: A total of 80 NAFLD patients and 41 healthy controls were included. Albumin binding function was significantly lower in NAFLD (ABiC: 196.00%, p < 0.001; IMA transformed (IMAT): 0.461, p < 0.001; and IMAT/albumin: 0.947 × 10-2, p < 0.001) than controls (ABiC: 211.00%; IMAT: 0.575; and IMAT/albumin: 1.206 × 10-2). Albumin binding function was also found to be significantly different among healthy participants and different severity groups of NAFLD (p < 0.001). Besides, albumin binding function showed positive correlation with BMI (ABiC: r = -0.247, p = 0.011; IMAT: r = -0.243, p = 0.013; IMAT/albumin: r = -0.254, p = 0.009) and FIB-4 index (ABiC: r = 0.230, p = 0.029). The ROC curve suggested that albumin binding function combined with BMI and triglyceride may predict the presence of NAFLD (area under ROC (AUROC) = 0.935, p < 0.001). CONCLUSION: Our findings suggest albumin binding function is a novel biomarker for early liver damage and disease progression in NAFLD.
PURPOSE: Indicators to assess early liver damage and disease progression in nonalcoholic fatty liver disease (NAFLD) remain unsatisfactory. Albumin binding function has been reported to be an early indicator of liver damage in hepatitis and liver cirrhosis. However, its role in NAFLD patients is unknown. METHODS: An age/sex-matched, case-control study was performed. Albumin-binding capacity (ABiC) and albuminmetal ion binding ability, assessed by ischemia modified albumin (IMA), were measured. Correlation analysis was performed to assess the association of albumin binding function with liver function enzymes and noninvasive liver fibrosis markers. RESULTS: A total of 80 NAFLD patients and 41 healthy controls were included. Albumin binding function was significantly lower in NAFLD (ABiC: 196.00%, p < 0.001; IMA transformed (IMAT): 0.461, p < 0.001; and IMAT/albumin: 0.947 × 10-2, p < 0.001) than controls (ABiC: 211.00%; IMAT: 0.575; and IMAT/albumin: 1.206 × 10-2). Albumin binding function was also found to be significantly different among healthy participants and different severity groups of NAFLD (p < 0.001). Besides, albumin binding function showed positive correlation with BMI (ABiC: r = -0.247, p = 0.011; IMAT: r = -0.243, p = 0.013; IMAT/albumin: r = -0.254, p = 0.009) and FIB-4 index (ABiC: r = 0.230, p = 0.029). The ROC curve suggested that albumin binding function combined with BMI and triglyceride may predict the presence of NAFLD (area under ROC (AUROC) = 0.935, p < 0.001). CONCLUSION: Our findings suggest albumin binding function is a novel biomarker for early liver damage and disease progression in NAFLD.
Entities:
Keywords:
Albumin Binding function; Albumin binding capacity (ABiC); Biomarker; ISCHEMIA-modified albumin (IMA); Non-alcoholic fatty liver disease
Authors: Louise Jm Alferink; Jessica C Kiefte-de Jong; Nicole S Erler; Bart J Veldt; Josje D Schoufour; Robert J de Knegt; M Arfan Ikram; Herold J Metselaar; Harry LA Janssen; Oscar H Franco; Sarwa Darwish Murad Journal: Gut Date: 2018-07-31 Impact factor: 23.059
Authors: Francesco De Chiara; Sara Heebøll; Giusi Marrone; Carmina Montoliu; Stephen Hamilton-Dutoit; Antonio Ferrandez; Fausto Andreola; Krista Rombouts; Henning Grønbæk; Vicente Felipo; Jordi Gracia-Sancho; Rajeshwar P Mookerjee; Hendrik Vilstrup; Rajiv Jalan; Karen Louise Thomsen Journal: J Hepatol Date: 2018-07-05 Impact factor: 25.083
Authors: Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón Journal: Front Med (Lausanne) Date: 2022-01-13